Roivant Sciences (NASDAQ:ROIV) Stock: Insider Daniel Allen Gold Sells 779,741 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Daniel Gold sold 779,741 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $39.14, for a total value of $30,519,062.74. Following the completion of the sale, the director directly owned 911,127 shares in the company, valued at $35,661,510.78. This trade represents a 46.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Daniel Allen Gold also recently made the following trade(s):

  • On Tuesday, November 17th, Daniel Gold sold 602,021 shares of Roivant Sciences stock. The shares were sold at an average price of $38.24, for a total transaction of $23,021,283.04.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $38.96 on Friday. Roivant Sciences Ltd. has a 1 year low of $19.96 and a 1 year high of $42.50. The firm has a 50-day moving average of $37.22 and a two-hundred day moving average of $32.59. The stock has a market cap of $28.23 billion, a price-to-earnings ratio of -61.84 and a beta of 1.23.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Alpine Bank Wealth Management acquired a new stake in shares of Roivant Sciences in the 3rd quarter valued at about $25,000. Compass Financial Management LLC acquired a new position in shares of Roivant Sciences during the 3rd quarter worth about $37,000. Kovack Advisors Inc. acquired a new stake in Roivant Sciences during the 3rd quarter valued at $47,000. Parallel Advisors LLC grew its stake in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after purchasing an additional 441 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, October 21st. HC Wainwright lifted their price objective on shares of Roivant Sciences from $47.00 to $48.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. UBS Group set a $55.00 price target on shares of Roivant Sciences in a research report on Wednesday, September 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 24th. Finally, Jefferies Financial Group raised their price target on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and an average target price of $46.82.

Check Out Our Latest Report on Roivant Sciences

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Read More

Insider Buying and Selling by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.